Barclays Has Lowered Expectations for Cellectis (NASDAQ:CLLS) Stock Price
Cellectis (NASDAQ:CLLS – Get Free Report) had its target price lowered by Barclays from $5.00 to $4.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price objective points to a potential upside of 189.86% from the stock’s current […]
More Stories
The Lincoln Lawyer is Renewed for Season 5: Will Manuel Garcia Return?
Netflix is back with its courtroom and lawyers. The Lincoln Lawyer season 5 renewal is announced. Showrunner Ted Humphrey and...
Heidi Klum Into the Spotlight After Naked Dress Spectacle at 68th Grammy Awards
If you like awards shows, then you must have watched the 68th Grammy Awards. The show was held on 1st...
President Trump Signs a Massive $1.2 Trillion Budget Deal at the Oval
President Donald Trump signed a $1.2 trillion (£880 billion) budget deal on Tuesday afternoon, 3 February 2026, in the Oval...
Freight Train Derails in Connecticut, Sending Cars Carrying Liquid Propane Into River
By The Associated Press MANSFIELD, Conn.—A freight train derailed Thursday in Connecticut, sending cars carrying flammable liquid propane into the...
Trump Calls for New Nuclear Arms Control Treaty as New START Expires
By Ryan Morgan U.S. President Donald Trump called for a new nuclear arms control treaty on Feb. 5, as the...
Bitcoin Slips Below $70,000 as Crypto Sell-Off Continues
By Andrew Moran Winter has arrived in the cryptocurrency market, as bitcoin has fallen below $70,000 for the first time...